Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
出版年份 2020 全文链接
标题
Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
作者
关键词
-
出版物
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-02-01
DOI
10.1007/s00018-020-03459-1
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
- (2019) Emmanuel S. Antonarakis ONCOLOGIST
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
- (2019) Bernardo Rapoport et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Tackling molecular targets beyond PD-1/PD-L1: Novel approaches to boost patients’ response to cancer immunotherapy
- (2019) Hany A. Omar et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
- (2019) Yue Song et al. Immunotherapy
- Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
- (2018) Michael C. Haffner et al. AMERICAN JOURNAL OF PATHOLOGY
- B7-H3 in tumors: friend or foe for tumor immunity?
- (2018) Gen Li et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
- (2018) Yinghao Zhao et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy
- (2018) Florent Amatore et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Immune checkpoint receptors: homeostatic regulators of immunity
- (2018) Antonio Riva et al. Hepatology International
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Joseph W. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
- (2018) Pedro Isaacsson Velho et al. Expert Review of Clinical Pharmacology
- Expression of Indoleamine 2,3-Dioxygenase Induced by IFN-γ and TNF-α as Potential Biomarker of Prostate Cancer Progression
- (2018) Irina Banzola et al. Frontiers in Immunology
- Biomarkers of response to immune checkpoint blockade in cancer treatment
- (2018) Takeo Fujii et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
- (2018) Angela Rita Elia et al. Frontiers in Immunology
- New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
- (2018) Michael A. Curran et al. Annual Review of Medicine
- Biomarkers for Programmed Death‐1 Inhibition in Prostate Cancer
- (2018) Charlotte Manogue et al. ONCOLOGIST
- Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
- (2018) Elena Gianchecchi et al. Frontiers in Immunology
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy
- (2017) Ravi A. Madan et al. Nature Reviews Urology
- Analysis of Tim-3 as a therapeutic target in prostate cancer
- (2017) Yongrui Piao et al. TUMOR BIOLOGY
- Depletion of regulatory T cells by anti-ICOS antibody enhances anti-tumor immunity of tumor cell vaccine in prostate cancer
- (2017) Lijun Mo et al. VACCINE
- Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
- (2017) Luc Cabel et al. Journal for ImmunoTherapy of Cancer
- LBA20ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL
- (2017) J. Mateo et al. ANNALS OF ONCOLOGY
- Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).
- (2017) T. M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis
- (2017) Na Li et al. Scientific Reports
- PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
- (2017) Dawn E. Dolan et al. Cancer Control
- Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse
- (2016) Valerio Nardone et al. CANCER BIOLOGY & THERAPY
- 4-1BB agonism: adding the accelerator to cancer immunotherapy
- (2016) Cariad Chester et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Molecular mechanisms involved in dendritic cell dysfunction in cancer
- (2016) Michael Tang et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Effects of radiation on metastasis and tumor cell migration
- (2016) Marta Vilalta et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Co-stimulatory and Co-inhibitory Pathways in Autoimmunity
- (2016) Qianxia Zhang et al. IMMUNITY
- The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy.
- (2016) Ashley Ross et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
- (2016) B Benzon et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Progression of benign prostatic hyperplasia is associated with pro-inflammatory mediators and chronic activation of prostate-infiltrating lymphocytes
- (2016) Melissa M. Norström et al. Oncotarget
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses
- (2016) Brian T. Rekoske et al. OncoImmunology
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors
- (2015) Anja Derer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
- (2015) Alberto Sada Japp et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
- (2015) A. Legat et al. CLINICAL CANCER RESEARCH
- Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
- (2015) Amer Assal et al. Immunotherapy
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
- (2015) Naomi B Haas et al. Journal for ImmunoTherapy of Cancer
- Targeting the indoleamine 2,3-dioxygenase pathway in cancer
- (2015) Yong Wha Moon et al. Journal for ImmunoTherapy of Cancer
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy
- (2014) Simone Muenst et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
- (2014) G. K. Philips et al. INTERNATIONAL IMMUNOLOGY
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients
- (2013) B. D. Curti et al. CANCER RESEARCH
- The Abscopal Effect Associated With a Systemic Anti-melanoma Immune Response
- (2013) Emily F. Stamell et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial
- (2013) Luana Calabrò et al. LANCET ONCOLOGY
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis
- (2013) Magdalena Kovacsovics-Bankowski et al. Journal for ImmunoTherapy of Cancer
- Immunotherapy and Immune Evasion in Prostate Cancer
- (2013) Archana Thakur et al. Cancers
- Combination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
- (2012) Kuang Youlin et al. Clinical & Developmental Immunology
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression
- (2012) Xin Gao et al. PLoS One
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
- (2011) Douglas G. McNeel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Ipilimumab
- (2011) Fiona Cameron et al. DRUGS
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Effects of 4-1BB signaling on the biological function of murine dendritic cells
- (2011) YOULIN KUANG et al. Oncology Letters
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
- (2009) L. Fong et al. CANCER RESEARCH
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
- (2009) Kathleen Ebelt et al. EUROPEAN JOURNAL OF CANCER
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Role of the BRCA2 Gene in Susceptibility to Prostate Cancer Revisited
- (2008) E. A. Ostrander et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model
- (2008) Ommoleila Molavi et al. IMMUNOLOGY AND CELL BIOLOGY
- Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124
- (2008) Ommoleila Molavi et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started